Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today released preliminary revenues for its second fiscal quarter of fiscal year 2013, ended February 28, 2013 (2QFY13).
Ms. Momoko Beran, chief financial officer of Simulations Plus, stated, “In accordance with our policy to release timely financial information to our shareholders, we are releasing preliminary revenues for 2QFY13. Net income will not be known until income taxes have been determined and our auditors review our Quarterly Report on Form 10-Q. We expect to file our 10-Q with the U.S. Securities and Exchange Commission on or before the April 14, 2013 deadline.”
Preliminary results for the quarter:
- This was the Company’s 22nd consecutive profitable quarter
- Preliminary revenues increased to $3.117 million, compared to $2.789 million in 2QFY12
- This represents an increase of 11.7% over 2QFY12 and is a new record quarter
- Approximately 18% of revenues came from new software licenses
- Approximately 6.4% of revenues came from consulting studies and collaborations
- Cash as of March 5, 2013 was $10.03 million
Walt Woltosz, chairman and chief executive officer of Simulations Plus, said: “The second quarter of fiscal year 2013 produced yet another record quarter-over-quarter result, with double-digit growth in revenues according to our preliminary numbers. New software license sales were strong, and our funded consulting contracts and collaborations have progressed smoothly. We remain financially very strong, with our cash at $10.03 million after paying out over $5.5 million in dividends in the past calendar year and $1.1 million in taxes in November, and we continue to have no debt.”